The Role of Allogeneic Stem Cell Transplantation in Relapsed/Refractory Hodgkin's Lymphoma Patients
Despite the favorable prognosis of most patients with Hodgkin's Lymphoma (HL), 15–20% of patients remain refractory to chemoradiotherapy, and 20–40% experience relapses following autologous stem cell transplantation (SCT) being used as salvage approach in this situation. Long-term survival of o...
Saved in:
Main Authors: | Evgeny Klyuchnikov, Ulrike Bacher, Nicolaus Kröger, Ilya Kazantsev, Tatjana Zabelina, Francis Ayuk, Axel Rolf Zander |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2011-01-01
|
Series: | Advances in Hematology |
Online Access: | http://dx.doi.org/10.1155/2011/974658 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Rationale and design of the multicenter, national, randomized, open labeled phase III trial: allogeneic stem cell transplantation as a potential curative treatment for patients with relapsed or progressed multiple myeloma (AlloRelapseMM Study)
by: Annemarie Glöckner, et al.
Published: (2025-01-01) -
Brentuximab Vedotin Treatment for Primary Refractory Hodgkin Lymphoma
by: Hung-Bo Wu, et al.
Published: (2013-01-01) -
Long-term survival and clinical implications of allogeneic stem cell transplantation in relapse/refractory lymphoma: A 20-year Singapore experience
by: Wei Sheng Joshua Loke, et al.
Published: (2025-01-01) -
Safety and efficacy of anti-CD30 CAR-T cell therapy in relapsed/refractory classic Hodgkin lymphoma: a systematic review and meta-analysis
by: Fanqiao Meng, et al.
Published: (2025-01-01) -
Severe Acute Pulmonary Toxicity Associated with Brentuximab in a Patient with Refractory Hodgkin’s Lymphoma
by: Yasmin Sabet, et al.
Published: (2016-01-01)